Intelligent Bio Solutions Files 8-K
Ticker: INBS · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1725430
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
IBSI filed a routine 8-K, no major news.
AI Summary
Intelligent Bio Solutions Inc. filed an 8-K on January 28, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as GBS Inc., is incorporated in Delaware and headquartered in New York. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a standard update for investors, indicating the company is meeting its regulatory reporting obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Intelligent Bio Solutions Inc. (company) — Registrant
- GBS Inc. (company) — Former company name
- Glucose Biosensor Systems (Greater China) Holdings, Inc. (company) — Former company name
- January 28, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as required by the SEC.
What were the previous names of Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. was formerly known as GBS Inc. and prior to that, Glucose Biosensor Systems (Greater China) Holdings, Inc.
When was the company incorporated and where is its principal executive office located?
The company was incorporated in Delaware and its principal executive offices are located at 135 West 41st Street, 5th Floor, New York, NY 10036.
What is the SIC code for Intelligent Bio Solutions Inc.?
The Standard Industrial Classification (SIC) code for Intelligent Bio Solutions Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Does this filing indicate any specific new business developments or financial results?
This filing does not specify any new business developments or financial results; it primarily serves as a regulatory disclosure and filing of exhibits.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-28 17:25:09
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 26KB
- ex99-1_011.jpg (GRAPHIC) — 10KB
- ex99-1_010.jpg (GRAPHIC) — 17KB
- ex99-1_008.jpg (GRAPHIC) — 23KB
- ex99-1_009.jpg (GRAPHIC) — 6KB
- ex99-1_003.jpg (GRAPHIC) — 19KB
- ex99-1_004.jpg (GRAPHIC) — 19KB
- 0001493152-25-004025.txt ( ) — 373KB
- inbs-20250128.xsd (EX-101.SCH) — 3KB
- inbs-20250128_lab.xml (EX-101.LAB) — 33KB
- inbs-20250128_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 28, 2025 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer